Ignite Creation Date:
2024-06-16 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06449885
Status:
RECRUITING
Last Update Posted:
2024-06-10
First Post:
2024-05-30
Brief Title:
A Cohort Study in Newly Diagnosed MZL
Sponsor:
Fudan University
Organization:
Fudan University
Study Overview
Official Title:
A Prospective Multi-center Cohort Study in Newly Diagnosed Marginal Zone B-cell Lymphoma
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Describe the clinical features diagnosis and treatment status disease course and primary outcomes of different subtypes of marginal zone B-cell lymphoma MZL observe the therapeutic efficacy and safety of different treatment modalities
Detailed Description:
Marginal zone lymphoma MZL originates from the marginal zone of lymphatic follicles and can occur in the spleen lymph nodes and mucosal lymphoid tissues and the incidence increases with age The clinicopathological features of each subtype of MZL are heterogeneous and their clinical manifestations biology etiology and treatment are all quite heterogeneous and there is still significant uncertainty about the optimal treatment pathway This prospective multicenter cohort study aims to describe the clinical features diagnosis and treatment status disease course and primary outcomes of different subtypes of MZL and to observe the therapeutic efficacy and safety of different treatment modalities
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None